A 10-Peptide Serum Improved Skin in 89.6% of Subjects Over 12 Weeks, Study Finds
A serum combining 10 peptides across two functional categories produced measurable improvements in facial and neck skin quality in a 12-week open-label trial, with 89.6% of subjects showing clinical improvement and 52.1% reaching moderate-to-marked global improvement by study end. The results, published in March 2026 in the Journal of Cosmetic Dermatology, also documented meaningful changes in the neck, an area infrequently addressed in cosmetic clinical literature. Roughness dropped by 41%, pigmentation by 35%, and fine lines by 32%.
The Logic Behind Combining 10 Peptides
The formulation, branded as Pep Up Collagen Boost Face & Neck Serum by Colorescience, uses a proprietary blend called Decaplex-10. The design is intentional: rather than stacking peptides for redundancy, the complex divides them into two functional directions.
Down-regulating peptides reduce overactive processes. Dipeptide diaminobutyroyl benzylamide diacetate inhibits neurotransmitter release to reduce repetitive muscle contractions at expression lines. Hexapeptide-2 suppresses enzymes involved in melanin synthesis, addressing uneven pigmentation at the source.
Up-regulating peptides stimulate collagen, elasticity, and hydration pathways. Copper tripeptide-1 functions as both a carrier and a regeneration signal. Palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 upregulate collagen synthesis pathways. Acetyl tetrapeptide-9 targets skin firmness; palmitoyl tripeptide-5 provides synergistic collagen support.
The standout is Sh-oligopeptide, a synthetic EGF-mimicking compound. It binds to EGF receptors and activates the same cell proliferation and repair signals as epidermal growth factor itself, while bypassing the stability issues and limited dermal penetration that constrain EGF protein in topical formulations. Tripeptide-10 citrulline and tripeptide-1 round out the complex, targeting glycation and expression-related skin changes.
Supporting ingredients include sodium hyaluronate, Tremella fuciformis extract (oxidative stress protection), oat extract (antioxidant and barrier reinforcement), and Physalis angulata extract (anti-inflammatory).
Who Participated and How
The trial enrolled 48 adults aged 18 to 75 (mean age 38.8, SD 13.5). Fitzpatrick skin types I through VI were all represented. 79.2% of participants were female, 20.8% male. At baseline, 85.4% described themselves as somewhat to extremely self-conscious about their skin.
Participants were split into two groups. Group A (n=24) had no prior use of professional or medical-grade skincare. Group B (n=24) had been using such products for at least 90 days. This split was deliberate: the researchers wanted to know whether the serum could deliver incremental benefit for users who were already receiving high-level skincare support.
Both groups applied the serum twice daily. Morning application (2 pumps face, 1 pump neck) was followed by SPF 50 sun protection. Assessments took place at weeks 4, 8, and 12.
What the Numbers Show
Week 4: 75% of subjects showed mild-to-moderate global improvement. No one had yet reached the threshold for marked improvement, but oiliness and texture changes were already being observed.
Week 8: Improvement rate rose to 87%. Between 21.7% and 30.4% of subjects had already crossed into moderate-to-marked territory.
Week 12: The final picture across facial parameters showed oiliness down 75% (from 1.33 to 0.33, p < 0.01), crepiness reduced by 35%, dryness by 34%, roughness by 28%, pigmentation by 27%, wrinkles by 23%, fine lines by 20%, and redness by 18%. Acne scarring improved by 62%. All improvements were statistically significant.
Investigator-assessed outcomes at week 12 showed glow and luminosity improved in 91.5% of subjects, dullness in 89.6%, skin tone in 89.6%, hydration in 83.3%, and laxity in 81.5%.
For the neck, the results were comparably strong. Smoothness improved in 94.4% of subjects by investigator assessment. Firmness reached 88.6%, fine lines 87.2%, hyperpigmentation 87.5%.
The Group That Already Had Good Skincare
Group B’s results carry practical weight. Subjects who had been using professional-grade products for months still showed improvement in 87.5% of cases, with 50% achieving marked improvement. The addition of the 10-peptide serum to an already functional regimen produced measurable clinical change. This is relevant for the large share of skincare users who are not starting from scratch but looking for targeted additions to existing routines.
Self-reported satisfaction aligned with the clinical data: 96% said their skin felt and looked healthier, 94% perceived improvement in how youthful their skin looked, and 83% reported feeling more confident about their skin. 91.7% said they would recommend the product.
Reading the Limitations Honestly
This was an open-label study, meaning both subjects and researchers knew what product was being used. Placebo effects cannot be excluded. The morning routine included SPF 50 sunscreen, making it difficult to fully isolate serum efficacy from UV protection alone. The researchers named both as limitations.
What the study adds, within those constraints, is specificity. Measuring 12 distinct facial parameters and 8 neck parameters separately, across two user groups with different baselines, produces a granular picture that single-outcome studies do not. The consistent trajectory from week 4 through 12, across both groups, is also harder to attribute to novelty effects alone.
For anyone already familiar with the peptide ingredient landscape, Sh-oligopeptide in a multi-peptide system validated against a professional skincare comparator group represents a design step worth watching. The broader question, whether this combination outperforms individual peptide actives in isolation, remains for future controlled trials to answer.
Study reference: Cayce et al., “An Open-Label Study to Assess the Efficacy and Tolerability of a Multifunctional, 10-Peptide Face and Neck Serum to Address Skin Quality,” Journal of Cosmetic Dermatology 25(3):e70746, March 2026. DOI: 10.1111/jocd.70746